BACKGROUND/AIM: Tumor endothelial marker 8 (TEM8) is a tumor endothelial-associated antigen that is having an increasingly recognized role in tumor biology. The expression of TEM8 in triple-negative breast cancer (TNBC) has not yet been characterized. MATERIALS AND METHODS: We hypothesize that TEM8 is overexpressed in TNBC and in metastatic TNBC in lymph nodes (LN) compared to normal breast tissue and normal lymphatic tissue, respectively. We studied expression of TEM8 in cases of primary (n=17) and metastatic (n=2) TNBC using immunohistochemical analyses. RESULTS: All cases demonstrated increased expression of TEM8 in tumor tissue compared to non-cancerous breast tissue. TEM8 was expressed at a higher level in the stroma adjacent to the TNBC in all cases, with focal immunoreactive areas within the tumor. TEM8 was not expressed in normal lymphoid tissue, but showed expression at sites of LN metastases. CONCLUSION: TEM8 would appear to represent a new biologic target for designing novel diagnostic or therapeutic approaches for TNBC.
BACKGROUND/AIM: Tumor endothelial marker 8 (TEM8) is a tumor endothelial-associated antigen that is having an increasingly recognized role in tumor biology. The expression of TEM8 in triple-negative breast cancer (TNBC) has not yet been characterized. MATERIALS AND METHODS: We hypothesize that TEM8 is overexpressed in TNBC and in metastatic TNBC in lymph nodes (LN) compared to normal breast tissue and normal lymphatic tissue, respectively. We studied expression of TEM8 in cases of primary (n=17) and metastatic (n=2) TNBC using immunohistochemical analyses. RESULTS: All cases demonstrated increased expression of TEM8 in tumor tissue compared to non-cancerous breast tissue. TEM8 was expressed at a higher level in the stroma adjacent to the TNBC in all cases, with focal immunoreactive areas within the tumor. TEM8 was not expressed in normal lymphoid tissue, but showed expression at sites of LN metastases. CONCLUSION:TEM8 would appear to represent a new biologic target for designing novel diagnostic or therapeutic approaches for TNBC.
Authors: Tiara T Byrd; Kristen Fousek; Antonella Pignata; Christopher Szot; Heba Samaha; Steven Seaman; Lacey Dobrolecki; Vita S Salsman; Htoo Zarni Oo; Kevin Bielamowicz; Daniel Landi; Nino Rainusso; John Hicks; Suzanne Powell; Matthew L Baker; Winfried S Wels; Joachim Koch; Poul H Sorensen; Benjamin Deneen; Matthew J Ellis; Michael T Lewis; Meenakshi Hegde; Bradley S Fletcher; Brad St Croix; Nabil Ahmed Journal: Cancer Res Date: 2017-11-28 Impact factor: 12.701
Authors: Christopher Szot; Saurabh Saha; Xiaoyan M Zhang; Zhongyu Zhu; Mary Beth Hilton; Karen Morris; Steven Seaman; James M Dunleavey; Kuo-Sheng Hsu; Guo-Jun Yu; Holly Morris; Deborah A Swing; Diana C Haines; Yanping Wang; Jennifer Hwang; Yang Feng; Dean Welsch; Gary DeCrescenzo; Amit Chaudhary; Enrique Zudaire; Dimiter S Dimitrov; Brad St Croix Journal: J Clin Invest Date: 2018-06-04 Impact factor: 14.808
Authors: David J Evans; Alexa M Wasinger; Robert N Brey; James M Dunleavey; Brad St Croix; James G Bann Journal: Front Oncol Date: 2018-11-06 Impact factor: 6.244
Authors: Sonia Alcalá; Paola Martinelli; Patrick C Hermann; Christopher Heeschen; Bruno Sainz Journal: Stem Cells Int Date: 2019-05-02 Impact factor: 5.443